双特异性抗体在结直肠癌治疗中的临床应用进展  

Progress in Clinical Application of Bispecific Antibodies in Colorectal Cancer Treatment

作　　者：刘欣 郑丽云[2,3] 楼立兰[3] 沈红璋 曹戟 潘红英 LIU Xin;ZHENG Liyun;LOU Lilan;SHEN Hongzhang;CAO Ji;PAN Hongying(Sir Run Run Shaw Hospital,School of Medical,Zhejiang University,Hangzhou 310013,China;Zhejiang University,Hangzhou 310058,China;Affiliated Hangzhou First People’s Hospital,Xihu University School of Medicine,Hangzhou 310006,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院,杭州310013 [2]浙江大学,杭州310058 [3]西湖大学医学院附属杭州市第一人民医院,杭州310006

出　　处：《中国现代应用药学》2024年第19期2735-2742,共8页Chinese Journal of Modern Applied Pharmacy

摘　　要：近10年来,结直肠癌(colorectal cancer,CRC)的发病率持续上升,给个人和社会带来了沉重的负担。尽管靶向及免疫治疗显著改善了CRC患者的临床预后,但耐药性及免疫应答率低等问题阻碍了其整体治愈率的进一步提升。双特异性抗体(bispecific antibody,BsAb)通过双靶点的设计有可能解决耐药及免疫应答的问题,成为近年来研究的热点。本文系统综述了目前用于CRC治疗的几种BsAb主要类型,并分述了BsAb的不同靶点及在CRC治疗中的临床应用进展。以期为后续用于CRC治疗的BsAb研究设计提供有益参考。The incidence of colorectal cancer(CRC)is increasing in the decade,which has caused a serious burden for the individual and society.Although the targeted therapy and immunotherapy has significantly improved the clinical prognosis of CRC patients,the problems of drug resistance and low immune response rate hinder its further development of overall cure rate.Bispecific antibody(BsAb)as a hot field recently,and the problems of drug resistance and low immune response might be solved through the design of double targets.In this paper,several main types of BsAb used for CRC treatment at present are systematically reviewed,the different targets of BsAb and its clinical application progress in CRC treatment are discussed.Trying to provide useful reference for the subsequent research and design of BsAb for CRC treatment.

关 键 词：双特异性抗体 结直肠癌 临床应用 

分 类 号：R966[医药卫生—药理学]